ALDR
T. Rowe Price Associates’s Alder Biopharmaceuticals, Inc. ALDR Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-633,121
| Closed | -$11.9M | – | 2592 |
|
|
2019
Q3 | $11.9M | Sell |
633,121
-7,060,998
| -92% | -$133M | ﹤0.01% | 1257 |
|
|
2019
Q2 | $90.6M | Sell |
7,694,119
-1,411,448
| -16% | -$16.6M | 0.01% | 677 |
|
|
2019
Q1 | $124M | Buy |
9,105,567
+1,393,489
| +18% | +$19M | 0.02% | 579 |
|
|
2018
Q4 | $79M | Buy |
7,712,078
+489,494
| +7% | +$5.02M | 0.01% | 664 |
|
|
2018
Q3 | $120M | Buy |
7,222,584
+5,359,871
| +288% | +$89.2M | 0.02% | 615 |
|
|
2018
Q2 | $29.4M | Buy |
1,862,713
+778,410
| +72% | +$12.3M | ﹤0.01% | 1070 |
|
|
2018
Q1 | $13.8M | Buy |
1,084,303
+5,024
| +0.5% | +$63.8K | ﹤0.01% | 1280 |
|
|
2017
Q4 | $12.4M | Buy |
1,079,279
+126,000
| +13% | +$1.44M | ﹤0.01% | 1287 |
|
|
2017
Q3 | $11.7M | Sell |
953,279
-32,250
| -3% | -$395K | ﹤0.01% | 1302 |
|
|
2017
Q2 | $11.3M | Buy |
985,529
+567,400
| +136% | +$6.5M | ﹤0.01% | 1298 |
|
|
2017
Q1 | $8.7M | Sell |
418,129
-17,500
| -4% | -$364K | ﹤0.01% | 1356 |
|
|
2016
Q4 | $9.06M | Buy |
435,629
+145,183
| +50% | +$3.02M | ﹤0.01% | 1334 |
|
|
2016
Q3 | $9.52M | Buy |
+290,446
| New | +$9.52M | ﹤0.01% | 1328 |
|
|
2016
Q2 | – | Sell |
-89,555
| Closed | -$2.19M | – | 2546 |
|
|
2016
Q1 | $2.19M | Sell |
89,555
-33,143
| -27% | -$812K | ﹤0.01% | 1503 |
|
|
2015
Q4 | $4.05M | Buy |
122,698
+60
| +0% | +$1.98K | ﹤0.01% | 1447 |
|
|
2015
Q3 | $4.02M | Buy |
122,638
+79,638
| +185% | +$2.61M | ﹤0.01% | 1467 |
|
|
2015
Q2 | $2.28M | Buy |
+43,000
| New | +$2.28M | ﹤0.01% | 1566 |
|